[Polymyalgia rheumatica and giant-cell temporal arteritis].
The article is dedicated to the contemporary concept of the prevalence, etiology, and pathogenesis of polymyalgia rheumatica and Horton's disease. The author analyzes the features of the pain syndrome, arthritis, fever, and other manifestations of the disease. Taking into consideration the fact that polymyalgia rheumatica and Horton's disease are usually revealed too late, the author pays special attention to their diagnostics and differential diagnostics. An increased ESR is a feature of this disease. Polymyalgia rheumatica is treated with prednisolone. The stages of glucocorticoid therapy, the rules of adjustment and lowering prednisolone doses, combined therapy with glucocorticoids and cytostatics, the effectiveness of therapy, and the prognoses are described in detail.
Tereshchenko
I V
IV
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D004334:Drug Administration Schedule; D013700:Giant Cell Arteritis / Q000188:drug therapy / Q000453:epidemiology* / Q000503:physiopathology*; D006801:Humans; D011111:Polymyalgia Rheumatica / Q000188:drug therapy / Q000453:epidemiology* / Q000503:physiopathology*; D011239:Prednisolone / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D011239:Prednisolone